YouTube Deep Summary
Extract content that makes a tangible impact on your life
Lightning Round: I want you to own D-Wave Quantum, says Jim Cramer
CNBC Television • 4:36 minutes • Published 2025-07-16 • YouTube
🤖 AI-Generated Summary:
📹 Video Information:
Title: Lightning Round: I want you to own D-Wave Quantum, says Jim Cramer
Duration: 04:36
Overview
This appears to be a transcript from Jim Cramer's "Lightning Round" segment where he quickly answers viewer questions about various stocks. The format involves rapid-fire stock recommendations and brief analysis of different companies brought up by callers from various locations.
Main Topics Covered
- Stock recommendations
- Mining companies (Agnico Eagle)
- Pharmaceutical stocks (Bristol-Myers)
- Cryptocurrency/fintech companies (Clean Spark)
- Dividend stocks (Flex LNG)
- D-Wave (quantum computing)
Key Takeaways & Insights
- Cramer suggests being selective with stock picks in the current market
- High dividend yields should be scrutinized for potential underlying issues
- Some speculative stocks can be worth considering if treated as speculation
- Market conditions appear to be favorable for certain stocks to make significant moves on positive news
Actionable Strategies
- Consider Agnico Eagle instead of New Gold for mining exposure
- Hold Bristol-Myers but monitor their central nervous system drug development
- Treat Clean Spark as a speculative play only
- Research thoroughly when encountering unusually high dividend yields
Specific Details & Examples
- Bristol-Myers described as "never seen it this cheap"
- Clean Spark mentioned as having 12 analyst buy ratings
- Flex LNG noted for its 13% dividend yield
- D-Wave described as capable of 10-point moves on positive news
Warnings & Common Mistakes
- Caution against assuming high dividends are automatically safe
- Warning about speculative nature of certain stocks like Clean Spark
- Need for due diligence when stocks appear unusually cheap
Resources & Next Steps
- Segment sponsored by Charles Schwab
- Suggestion to research more deeply into companies with unusually high dividends
- Importance of following up on specific company developments (like Bristol-Myers' CNS drug)
📝 Transcript (138 entries):
[00:03] brilliantly. >> I don't know how much that sounds. And then the lightning round is over. Are you ready? Ski. I'm gonna start with Lewis
[00:25] in Pennsylvania. Lewis. Hi there. Jim. I'm from.
[00:29] >> Outside Philadelphia, near [00:31] the home of your buddy, Jeff [00:32] Lurie. Are you picking up. >> Nice over there? It's nice there. Over there. Just
[00:38] fantastic. What's going on? >> Yes. What do you think about new goals? >> It's okay. I mean, why not
[00:43] buy Agnico Eagle? That's the one I really, really like. They're doing so well. Let's go with Agnico. I need to go to Chip in Mississippi. Chip.
[00:52] >> Hey, what's up man? >> Not much. How about you? I'm chilling. Little.
[00:56] >> It's pretty hot here. I'm chilling. Hey, listen, I heard Blue Horseshoe liked some shorts, so I bought some. It's done really well over the last couple of weeks. So my question is, do you think I'm better off selling my rig? Which seems like
[01:09] I've been averaging down for a [01:10] year and a half. >> And I want you to own this D-Wave. Here's why I want D-Wave. Because one headline, one little story, and that stock goes up ten points. I mean, I'm looking at stuff that is going up ten points on nothing. And
[01:24] D-Wave has the ability to be [01:25] able to do that because it's [01:27] actually a real company. Let's go to Rick in Wisconsin. Rick. >> Hi, Jim. Rick from Wisconsin.
[01:33] >> All right. What's up? Thank you. >> It's my first time in Cramerica. Oh.
[01:38] >> Good to have you. >> My worst performing tryptic. My worst performing stock does does have a nice dividend but isn't doing much else in a bull market, although it was up today. Should I sell, hold or even add to Bristol-Myers? >> All right. Bristol-Myers.
[01:55] Never seen it this cheap. We're holding it. I did have high hopes for there. What I would say is their central nervous system drug. It better work. If
[02:04] it doesn't work, we're going to [02:06] get rid of it, and it will be a [02:09] disappointment. And it will be a shame. Let's go to Chad in Wisconsin. Chad. >> Hey, Jim. Thanks for taking
[02:13] my call. >> Of course. Chad. >> What's up? Hey, you know, I had to get your thoughts and opinions on this under the radar stock. It's currently rated by
[02:22] many as a strong buy by at least [02:25] 12 analysts. It's a bitcoin fintech energy infrastructure company. It's raised about 50% below its price target. Even JP Morgan Chase and Citi have much higher price targets. It seems like it's on the verge of a breakout. What is your thoughts
[02:38] on Clean Spark? >> Okay. All right. Clean spark is another one of these stocks that I mean, frankly, I didn't even know J.P. Morgan followed
[02:46] that one. I'm not so sure they do. It's another one of those stocks that when the headline is going to roll. So I now say it's okay to have a speculative look. You can speculate with it as long as you understand that it's speculation and nothing more.
[02:58] Let's go to Greg in Michigan. Greg. >> Booyah Jimmy chill. >> Yo, man. >> What you hear.
[03:05] >> What's happening? >> Hey listen, I've been I've been watching you for 20 years and look forward to watching you 20 more. My man. >> I love it. I'll go.
[03:13] >> For it. Thanks for all you do. And thank thanks for everything I got. I recently retired, I've been watching this company for a little over a year. It's got a big fat, juicy dividend of 13% and it's called flex LNG.
[03:30] >> Yeah, I've been trying to [03:31] figure out why that has such a [03:34] big dividend. Let me go to work on that for you rather than just say, well I think that dividend is safe. We got to find out. When you see dividend that high versus the rest of the market, there might be something wrong. We're going to get on it. And
[03:46] that, ladies and gentlemen, is [03:47] the conclusion of the Lightning [03:49] round. >> The Lightning Round is sponsored by Charles Schwab. Coming up, even when the stock is down, it may not be out. Cramer speaking out against the market's prevailing thought pattern when it comes to post earnings declines next.